We went through the published human NMN trials to see what side effects were actually recorded, at what doses, and what nobody has tested yet.
In the human trials published so far, NMN has been well tolerated at 250 mg to 2,000 mg a day, with adverse events no more common than on placebo. But those trials are small (usually 10 to 110 people), short (two weeks to three months) and often funded by NMN makers, so long-term safety is simply unknown. People who are pregnant, being treated for cancer, or taking diabetes or blood pressure medicines should talk to their doctor first.
Nicotinamide mononucleotide (NMN) is a building block your body uses to make NAD+, a molecule involved in energy metabolism and cell repair. NMN supplements are sold on the idea that raising NAD+ may support healthy aging. If you are new to the topic, our complete guide to NMN as an NAD+ precursor covers the basics.
On safety, the honest summary is "no red flags so far, but not much data." A 2023 review in Advances in Nutrition by Song and colleagues pulled together the human trials and concluded that oral NMN appears safe and well tolerated. The same authors stressed that the trials were small, mostly short-term, and that more long-term toxicology work is needed.
Here are the main published trials with the doses, lengths and safety findings they reported.
| Study | Who took part | Dose and length | Safety finding |
|---|---|---|---|
| Keio University single-dose study (Japan) | 10 healthy men, 40 to 60 | One dose of 100, 250 or 500 mg | No significant adverse effects; bilirubin rose slightly but stayed in the normal range |
| Yoshino et al., 2021 (US) | 25 postmenopausal women with prediabetes | 250 mg a day for 10 weeks | Adverse events were not a main focus; no safety concerns were highlighted |
| Fukamizu et al., 2022 (Japan) | 31 healthy adults, 20 to 65 | 1,250 mg a day for 4 weeks | 5 adverse events, none judged related to NMN; blood, urine and body measurements stayed within normal variation |
| Yi et al., 2022 | 80 healthy adults, 40 to 65 | 300, 600 or 900 mg a day for 60 days | No safety problems reported at any of the three doses |
| Igarashi et al. (Japan) | 42 healthy men, 65 and older | 250 mg a day for 12 weeks | No obvious adverse effects |
| Pencina et al., 2023 (US) | 30 overweight or obese adults, 45 and older | 1,000 mg twice a day (2,000 mg total) for 28 days | Adverse events similar to placebo |
A few patterns stand out. The highest dose tested for about a month is 2,000 mg a day, in a pharmaceutical-grade form called MIB-626. The longest trials ran about three months. Nobody has published results on people taking NMN for a year or more, which is how most buyers actually use it.
Funding matters too. The Fukamizu safety study was paid for by Mitsubishi Corporation Life Sciences, which supplied the NMN, and five of its six authors worked there. The Yi trial was co-sponsored by the companies that make the NMN ingredient it tested. Industry funding does not make results wrong, but independent replication would carry more weight. For what these trials showed on benefits, see our article on whether NMN works and the clinical evidence behind it.
Formal trials did not find a consistent side-effect pattern. Outside of trials, the complaints that come up with NAD+ precursors tend to be mild and digestive or energy-related:
Treat this list as "things to watch for," not as proven effects. None of them showed up more often than placebo in the controlled trials above, and the trials were too small to pick up rare reactions.
The biggest gap is time. Three months of data cannot tell you about effects that build up over years. The 2023 review specifically called for longer human studies.
NAD+ supports energy production in all cells, including cancer cells. The Song review notes that some animal and cell studies raised possible concerns, such as effects on inflammatory signals from aging cells and on certain nerve-cell pathways. These findings are from lab models, not people, but they are the reason many doctors advise against NAD+ boosters for anyone with active cancer or a history of it.
NMN is a form of vitamin B3. When the body clears extra B3, it makes metabolites including one called 4PY, and the Keio single-dose study saw these rise after NMN. In 2024, a Cleveland Clinic team reported in Nature Medicine that higher 4PY levels were associated with heart attack and stroke risk, and that 4PY caused vascular inflammation in preclinical tests. That study looked at niacin, not NMN supplements, and showed an association rather than proof of harm. It is a reasonable open question, not a known risk.
Supplements are not checked by the FDA before sale. Purity, actual NMN content and contamination vary between brands, so a third-party certificate of analysis matters more with NMN than with a basic vitamin.
Known drug interactions have not been formally studied for NMN. That is not the same as having none. Bring the bottle to your doctor or pharmacist if you take any regular medication, including blood thinners.
In late 2022 the FDA said NMN could not be sold as a dietary supplement because it had first been investigated as a drug. On September 29, 2025, after a citizen petition and lawsuit by the Natural Products Association, the FDA reversed that position and said NMN is not excluded from the supplement definition. That decision is about legal status, not safety. NMN is still a supplement that has not been approved or evaluated by the FDA for any health use.
Based on the published trials, NMN at 250 mg to 1,250 mg a day looks well tolerated for up to about three months in healthy adults, and up to 2,000 mg a day has been tested for four weeks. That is reassuring but limited: small groups, short timelines and frequent industry funding.
If you are healthy and want to try it, a moderate dose (most trials used 250 to 600 mg), taken earlier in the day with food, is the conservative approach. Skip it if you are pregnant or have cancer, and talk to your doctor first if you take diabetes, blood pressure or other regular medicines. Stop if you notice anything unusual.